Quanterix Corp
NASDAQ:QTRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
IGB Commercial Real Estate Investment Trust
KLSE:IGBCR
|
MY |
|
Bexcellent Group Holdings Ltd
HKEX:1775
|
HK |
|
F
|
Furukawa Electric Co Ltd
TSE:5801
|
JP |
|
K
|
Kaushalya Infrastructure Development Corporation Ltd
BSE:532925
|
IN |
|
ipet Holdings Inc
TSE:7339
|
JP |
|
L
|
Lypsa Gems & Jewellery Ltd
NSE:LYPSAGEMS
|
IN |
|
Seikagaku Corp
TSE:4548
|
JP |
|
Izmo Ltd
NSE:IZMO
|
IN |
|
Shake Shack Inc
NYSE:SHAK
|
US |
|
Arriyadh Development Company SJSC
SAU:4150
|
SA |
|
S
|
SK Eternix Co Ltd
KRX:475150
|
KR |
|
M
|
Medicalgorithmics SA
WSE:MDG
|
PL |
|
Art's Way Manufacturing Co Inc
NASDAQ:ARTW
|
US |
|
Brisa Bridgestone Sabanci Lastik Sanayi ve Ticaret AS
IST:BRISA.E
|
TR |
Quanterix Corp
Research & Development
Quanterix Corp
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Quanterix Corp
NASDAQ:QTRX
|
Research & Development
-$35.9m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Research & Development
-$1.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Danaher Corp
NYSE:DHR
|
Research & Development
-$1.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-6%
|
|
|
Waters Corp
NYSE:WAT
|
Research & Development
-$195.7m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-5%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Research & Development
-$454m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-4%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Quanterix Corp
Glance View
Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 460 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to reliably detect protein biomarkers at extremely low concentrations in blood, serum and other fluids. Its products include HD-X Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, and 2470 Arrayer. The company also supplies NF-Light antibodies and ELISA kits, which offer solutions for the detection of neurofilament light (Nf-L) for the development of therapeutics and diagnostics for neurodegenerative conditions. Its portfolio of available kits spans multiple therapeutic areas, including cardiology, infectious disease, inflammation, neurology, and oncology. The company provides services through its Simoa Accelerator Laboratory.
See Also
What is Quanterix Corp's Research & Development?
Research & Development
-35.9m
USD
Based on the financial report for Dec 31, 2025, Quanterix Corp's Research & Development amounts to -35.9m USD.
What is Quanterix Corp's Research & Development growth rate?
Research & Development CAGR 5Y
-12%
Over the last year, the Research & Development growth was -16%. The average annual Research & Development growth rates for Quanterix Corp have been -12% over the past three years , -12% over the past five years .
